Clinical Trial Update: Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update describing a blood-based tumor DNA test to identify HR+/HER2-low metastatic breast cancer patients who may be candidates for tra…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: UNICANCER | Conditions: Breast Cancer Metastatic, Breast Cancer Stage IV | Phase 2 | Status: ENROLLING_BY_INVITATION